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Abstract
Metabolic research has, like most areas of research in the life sciences, been affected dramatically by the application of
transgenic technologies. Within the specific area of bioenergetics it has been thought that transgenic approaches in mice
would provide definitive proof for some longstanding metabolic theories and assumptions. Here we review a number of
transgenic approaches that have been used in mice to address theories of mitochondrial efficiency. The focus is largely on
genes that affect the coupling of energy substrate oxidation to ATP synthesis, and thus, mice in which the uncoupling protein
(Ucp) genes are modified are discussed extensively. Transgenic approaches have indeed provided proof-of-concept in some
instances, but in many other instances they have yielded results that are in contrast to initial hypotheses. Many studies have
also shown that genetic background can affect phenotypic outcomes, and that the upregulated expression of genes that are
related to the modified gene often complicates the interpretation of findings. ß 2001 Elsevier Science B.V. All rights
reserved.
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1. Introduction
The application of transgenic technologies in life
science research has become widespread. Within the
¢eld of bioenergetics and metabolism it has been ex-
pected that their application would provide de¢nitive
evidence for many longstanding metabolic hypo-
theses and theories. The expectation is generally
founded on one of the prevailing bene¢ts of trans-
genic technologies ^ the ability to decipher the im-
portance of a speci¢c protein under physiological
conditions, in vivo. While this is clearly an advantage
over more traditional in vitro cellular and molecular
approaches, the latter approaches still remain neces-
sary for the characterization of metabolic pathways
under normal and diseased states. It is also impor-
tant to recognize that most metabolic diseases have
polygenic origins and are a¡ected often by environ-
mental factors (e.g. diet), and thus their elucidation
will only be advanced in part by transgenic ap-
proaches. Interestingly, in many instances, rather
than providing the proof for longstanding theories,
transgenic approaches have produced results that call
into question some well established metabolic con-
cepts.
1.1. Aim and de¢nitions
The aim in this review is not to detail transgenic
technologies, but to review what useful ¢ndings have
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emerged from their application to the study of mito-
chondrial energetics. Speci¢cally, we will address the
question: how has the application of transgenics im-
proved our understanding of the factors a¡ecting the
e⁄ciency of mitochondrial energetics? The term ‘mi-
tochondrial e⁄ciency’ is used in the context of the
e⁄ciency of energy transduction. In itself, it conveys
the now well recognized fact that there is indeed sig-
ni¢cant variation in the degree to which mitochon-
dria produce ATP from a given amount of energy
substrate, originating from dietary fat, carbohydrate
and protein. The major mechanisms a¡ecting mito-
chondrial e⁄ciency comprise uncoupling protein
(UCP)-mediated proton leaks, and proton leaks hav-
ing other origins. Both have been proposed to de-
crease the e⁄ciency of mitochondrial ATP synthesis
(oxidative phosphorylation), but the degree to which
the two are distinct is currently a much debated
topic, as discussed by others in this monograph.
The control and regulation of oxidative phosphory-
lation will also be described by others within this
monograph, as will the pathologic and more rare
mechanisms underlying variation in mitochondrial
energetic e⁄ciency, e.g. mitochondrial cytopathies.
Before proceeding however, some fundamental
concepts should be reviewed. Regardless of the spe-
ci¢c mechanism, the uncoupling of oxidative phos-
phorylation results in the release of energy in the
form of heat. Heat production (thermogenesis) re-
sults directly from substrate oxidation, and is a nor-
mal and advantageous byproduct of mitochondrial
energetics, particularly in endothermic species.
When oxidative phosphorylation is well coupled,
thermogenesis is positively correlated to the amount
of ATP synthesis, and to the rate of substrate oxida-
tion (and thus tissue oxygen consumption). However,
during uncoupled oxidative phosphorylation, ther-
mogenesis correlates only with the rate of energy
substrate oxidation. Because the route of proton re-
turn to the matrix bypasses ATP synthase in un-
coupled states, oxygen consumption is clearly unre-
lated to (uncoupled from) ATP synthesis.
1.2. Implications of uncoupling for mammalian energy
metabolism ^ a historical perspective
At the level of the whole animal, uncoupling af-
fects both thermoregulation and fuel e⁄ciency. Ther-
moregulation can be de¢ned as the ability of the
animal to adjust its heat production and heat loss
in accordance with changes in environmental temper-
ature to maintain its body temperature. Fuel e⁄-
ciency at the level of the whole animal refers to the
proportion of dietary energy that is ultimately avail-
able for use by the animal [3]. Uncoupled oxidative
phosphorylation is the hallmark feature of metabo-
lism in brown adipose tissue (BAT) where the pres-
ence of UCP1, in concert with unique anatomical
features of the tissue, allows a profound degree of
thermogenesis [35,39]. As will be discussed below in
the context of the Ucp1 knockout mouse, UCP11-
mediated uncoupling is necessary for the acute in-
crease in thermogenesis on exposure to cold. Because
of the high rates of fuel oxidation and heat produc-
tion that occur when BAT is fully active, uncoupled
energy metabolism a¡ects energy expenditure, espe-
cially in small rodents where energy expenditure is
often doubled or tripled when animals are cold-accli-
mated. In humans, BAT is present in large amounts
in newborns and plays an important role in the adap-
tation to postnatal ambient temperatures, but by
adulthood only small amounts remain [35,39].
A state of energy balance exists when an animal’s
dietary energy intake equals its energy expenditure.
When energy intake chronically exceeds energy ex-
penditure, the surplus is stored mainly as adipose
triacylglycerol. The outcome of uncoupling is in-
creased energy expenditure; the energy is simply re-
leased as heat. Thus uncoupling has implications for
energy balance, and for this reason, there has been a
longstanding interest in the role of uncoupled energy
metabolism in the development, and the potential
treatment, of obesity. That uncoupled energy metab-
olism in BAT could play a signi¢cant role in the
development of [37] and resistance to [75] obesity
was well demonstrated over 20 years ago. Recent
studies using L-3-adrenergic agonists in rodents to
stimulate brown adipose thermogenesis demonstrate
that an acute dose can double resting energy expen-
diture, and that chronic treatment with agonist re-
sults in recruitment of Ucp1-expressing thermogenic
brown adipocytes in white adipose tissue (WAT) de-
1 Uppercase and lowercase letters will be used to denote the
protein and the gene (or mRNA thereof), respectively.
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pots that normally contain only white adipocytes
[20]. There is much interest in the possibility that
L-3-adrenergic agonists may be used to recruit ther-
mogenic adipocytes in WAT of adult humans to
treat obesity and mature-onset diabetes.
The extensive uncoupling and thermogenesis that
can be achieved in BAT was described in scienti¢c
literature long before the identi¢cation of the protein
thought to cause the uncoupling. In the early 1960s
the thermogenic function of BAT was identi¢ed [79].
It was almost another 20 years before UCP (referred
to as UCP1 following the identi¢cation of newer
members of the gene family) was isolated [62,72]
and cloned [5,6,42,71]. While a lesser degree of un-
coupling was described for mitochondria from tissues
other than BAT in animals not exposed to cold, the
uncoupling was initially perceived as an artifact of
mitochondrial isolation. However, in the late 1980s
and early 1990s, Brand and colleagues showed that
the uncoupling is physiologic, and is regulated by a
number of factors known to a¡ect total body energy
metabolism (e.g. thyroid hormones) [31^33,63]. This
process, referred to as mitochondrial proton leak,
has been estimated to account for 20^50% of resting
metabolic rate in rats [8,73,74]. The hypothesized
mechanism for leak and factors a¡ecting the regula-
tion of leak will be reviewed by others in this mono-
graph, and only the fundamental discoveries will be
introduced here.
In the search for mechanisms underlying mito-
chondrial proton leak, a number of proteins that
are homologous to UCP1 were identi¢ed. There are
now ¢ve putative UCPs. Ucp2 is expressed in most
tissues of humans and rodents [16,21]. Ucp3 is ex-
pressed preferentially in skeletal muscle of humans;
in rodents it is also expressed in BAT [7,91]. UCP2
and UCP3 have considerable homology with UCP1 ^
roughly 57^59%. Ucp4 is expressed in the brain, and
not in any of the other many tissues probed [55]. The
¢fth putative member is brain mitochondrial carrier
protein 1 (Bmcp1), and it is expressed mainly in the
brain, but also in other tissues to a minor extent [76].
The homologies of UCP4 and BMCP1 with UCP1
are approximately 34%. BMCP1 is increasingly being
referred to as UCP5, and very recent ¢ndings corre-
late UCP5 expression with metabolic rate [1,93]. De-
spite the proliferation of studies on the novel UCPs
(approximately 400 papers published since 1997) (re-
viewed in [7,38,78,82]), little is known about their
true physiologic function. It has been expected that
the application of transgenic methods (reviewed be-
low) would shed considerable light on this area.
Prior to the development of transgenic methods,
studies aimed at elucidating the physiological signi¢-
cance of uncoupled metabolism in BAT employed
dietary, environmental temperature and pharmaco-
logic methods to modify the activities of uncoupling
processes. Overfeeding was shown to induce the ex-
pression of Ucp1 and increased uncoupling activity
in BAT; this is referred to as diet-induced thermo-
genesis, and it was proposed as a metabolic mecha-
nism favoring leanness [75]. The exposure to environ-
mental cold is well known to result in increased
UCP1 protein and uncoupling activity in BAT mito-
chondria, and in the appearance of Ucp1-expressing
adipocytes in adipose tissue depots that normally
contain only white adipocytes. Rodents that are
housed at thermoneutrality (approximately 31‡C for
mice, and 28‡C for rats) on the other hand have no
need for thermoregulatory heat production, and it
has been shown that UCP1 expression and activity
are low under such conditions. A number of studies
of the thermogenic e¡ects of L-3-adrenergic agonists,
and studies of speci¢c hormone and disease states
(thyroid hormones; pheochromocytoma) have corro-
borated the generally well accepted opinion that un-
coupled BAT metabolism, at least in rodents, was
important with respect to obesity and thermoregula-
tion [35]. It is generally well accepted that noradrena-
line, secreted by the sympathetic nerves that inner-
vate BAT, is responsible both for the acute
thermogenic response of the brown adipocytes and
for the hypertrophy of BAT that occurs in response
to chronic stimulation. This hypertrophy involves
proliferation of precursor cells and then di¡erentia-
tion, marked mitochondriogenesis in new and old
brown adipocytes and a concomitant upregulated ex-
pression of Ucp1. The thermogenic capacity of BAT
increases to the extent that it can sustain in mice a
3.5-fold increase in whole body heat production at a
temperature of 5‡C in the absence of shivering [65].
In the warm acclimated mouse, an increase in whole
body heat production can still occur, to almost the
same extent as in the cold-acclimated mouse, but in
this case the increased heat production occurs in the
shivering skeletal muscles, as well as, to a much less-
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er extent, in BAT. Because of the clear importance of
BAT towards energy expenditure in rodents there
was substantial support for the hypothesis that
UCP1-mediated uncoupling is relevant to obesity
prevention.
1.3. Transgenic approaches
Transgenic approaches have a particular advan-
tage over traditional approaches in that they some-
times allow unequivocal answers to questions of the
importance of a speci¢c protein under physiological
conditions, in vivo. The term ‘transgenic’ is used here
to describe mice in which recombinant DNA tech-
nology is used to remove a gene (or part of a gene),
or in which a gene is overexpressed through the
transfer of a foreign gene construct. The resulting
mice are commonly referred to as either ‘knockout’
or ‘overexpression’ mice, respectively, for a particu-
lar gene. Several good reviews of mammalian trans-
genic technologies are available [9,51,53].
One of the di⁄culties encountered with the use of
‘knockout’ mice in the elucidation of a speci¢c pro-
tein’s physiological function is that another gene may
encode a protein having a homologous function, and
the expression of the homologue may be upregulated
as a result of the removal of the targeted gene. The
outcome may be partial, or even complete compen-
sation, and the conclusions drawn may then under-
estimate the true physiological importance of the tar-
geted gene. Another fundamental and common
problem is that the removal of the gene product
may interrupt normal embryonic development, pre-
cluding postnatal life.
Transgenic mice in which genes are overexpressed
through the transfer of a foreign gene construct also
have inherent advantages and disadvantages. ‘Over-
expression’ mice can be produced relatively quickly,
but are associated with the unpredictable integration
of the transgene into the genome. As a result, multi-
ple copy numbers of the transgene can be incorpo-
rated, and there is often no control over the integra-
tion site in the genome.
In summary then, the main advantage of transgen-
ic approaches over the traditional in vitro cellular
and molecular approaches is that the former provide
information about the importance of a speci¢c pro-
tein at the level of the whole animal. However, as
will be elaborated upon during the discussion of spe-
ci¢c transgenic models, studies of transgenic mice are
replete with complexities stemming predominantly
from redundancies, or ‘back-up’ mechanisms within
metabolic systems. Consequently, mouse phenotypes
need to be interpreted with an integrative under-
standing of metabolism and physiology. Despite the
above described limitations and potential problems,
the application of transgenic technologies has gener-
ated resourceful information on mitochondrial ener-
getics.
2. Transgenic alterations in mitochondrial proteins
a¡ecting the e⁄ciency of energy transduction
A number of transgenic approaches have been
used to study mitochondrial e⁄ciency. First to be
considered will be the approaches used to modify
genes that are linked to mitochondrial uncoupling
through direct e¡ects on mitochondrial proteins.
There are also several examples of transgenic mod-
i¢cation of extramitochondrial factors which impinge
on mitochondrial e⁄ciency; these will be discussed
afterwards. Table 1 outlines, within these categories,
the speci¢c transgenic models that will be described
here.
2.1. Removal or relative absence of UCPs
2.1.1. Transgenic ablation of cells expressing UCP1
Since it had not been feasible using traditional
metabolic approaches to assess the function of the
recently identi¢ed UCPs in their physiological envi-
ronment, it was hoped that studies of transgenic mice
that lack the UCPs might clarify their physiological
function. The ¢rst attempt was in the early 1990s and
used transgenic ablation of Ucp1-expressing adipo-
cytes in mice with a FVB/N genetic background [52].
Cell ablation was achieved by linking the expression
of diphtheria toxin A (DTA) to the Ucp1 promoter;
thus Ucp1-expressing cells were killed. Based on the
extensive literature describing the importance of
UCP1 in rodents for energy balance and thermoreg-
ulation, it was anticipated that these mice would be
obese and cold-intolerant. The mice, referred to as
UCP-DTA mice, were indeed obese and, surpris-
ingly, hyperphagic. It was also surprising that the
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UCP-DTA mice were not cold-intolerant. Despite a
blunted increase in total body oxygen consumption
in response to an acute dose of L-3-adrenergic ago-
nist, the mice were able to tolerate the exposure to
cold (4‡C).
Interestingly, the ablation of Ucp1-expressing cells
in UCP-DTA mice was not complete; only 60% of
the UCP1-expressing cells were removed. Thus the
obesity observed is intriguing ^ particularly when
one considers the metabolic phenotypes of the
Ucp1 knockout mouse, and the Ucp3 knockout
mouse (described below). The obesity in the UCP-
DTA mouse is accompanied by the common meta-
bolic sequellae of obesity, and include high circulat-
ing leptin levels, leptin resistance of feeding, insulin
resistance, and hyperlipidemia [17,18,28,29]. The reg-
ulation of hypothalamic neuropeptides by leptin ap-
pears fairly normal and some other defect in control
of food intake is suggested [54,88]. A role for BAT in
a leptin-independent control of food intake has been
suggested on other grounds [57,58]. These studies
with UCP-DTA mice suggested that the relative
lack of UCP1 function might lead to hyperphagia
as well as obesity. It must however be remembered
that the ablation of Ucp1-expressing cells would also
ablate other UCPs that are also present in UCP1-
expressing brown adipocytes. The possibility that
the transgene may have been inappropriately ex-
pressed, or inserted into a gene associated with leptin
signaling has also been discussed [47]. Consistent
with the latter possibility is the fact that another
line of UCP-DTA mice that was described in the
original report (Ucp176 line; [52]) was not hyperpha-
gic, and showed a transient obesity. Further investi-
gations using this mouse model of obesity are
needed.
2.1.2. The Ucp1 knockout mouse
The metabolic characteristics of UCP-DTA mice
suggested that the complete removal of Ucp1
through gene knockout technologies might lead to
profound obesity in mice. However, the Ucp1-de¢-
cient, or ‘knockout’, mouse showed that this, surpris-
ingly, is not the case [14]. The targeted inactivation
of the Ucp1 gene was achieved through homologous
recombination. The mice have no mRNA for Ucp1
of normal size, as assessed by Northern blot analy-
sis, or by reverse transcription-PCR. As expected
though, the mice are cold-intolerant, as demon-
strated by their inability to maintain normal body
temperature when exposed to 4‡C. Consistent with
the latter was the observed blunted response in total
body oxygen consumption to the administration of
an acute dose of a L-3-adrenergic agonist.
The ¢nding that Ucp1 knockout mice show no
enhanced susceptibility for obesity even when fed a
high fat (58 kcal%) diet is remarkable, particularly in
light of their defective thermogenesis. In contrast to
the UCP-DTA approach described above, in the
Ucp1 knockout mouse the UCPs other than UCP1
Table 1
Some transgenic mouse models relevant to studies of mitochondrial e⁄ciency
Cellular location Transgenic modi¢cation Referencesa
(A) Mitochondrial
(i) Removal or reduction Ucp1 toxigene (Ucp-DTA) [17,18,28,29,47,52,57,58]
Ucp1 knockout [14,47,56,59]
Ucp3 knockout [23,90]
Ucp1^Ucp3 double knockout [23]
Ucp2 knockout ^
Ant1 knockout [15,25]
(ii) Overexpression or ectopic expression aP2-UCP1 ectopic [45,46,81]
hUcp3 overexpression [10]
(B) Extramitochondrial
(i) Removal or reduction PKA-RIIL knockout [2,11,66]
Hormone-sensitive lipase knockout [64,92]
L-3-Adrenergic receptor knockout [27,40,69,85]
Dopamine L hydroxylase knockout [86,87]
(ii) Overexpression Glut4 overexpression [89]
aReference numbers in bolded font indicate the ¢rst publication reporting the transgenic mouse model.
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would remain intact. It is important to also note that
these initial experiments were conducted on mice
having a mixed 129/Sv Pas and C57BL6J genetic
background. Genetic background appears to have
signi¢cant consequences on the resulting phenotypes.
Kozak and colleagues have now placed the targeted
allele on several de¢ned genetic backgrounds, such as
C57BL6, 129/SvImJ and BALB/cBy [47]. Their as yet
unpublished results show profound e¡ects of genetic
background on cold-intolerance in the di¡erent lines
of Ucp1 knockouts. Studies relating to possible ef-
fects of background on the susceptibility to obesity
are in progress.
A number of groups have begun to examine the
implications of the absence of UCP1 for bioener-
getics at the level of isolated mitochondria and cells
from BAT. The ¢rst was Monemdjou et al. [59] who
showed that proton leak in mitochondria isolated
from BAT of Ucp1 knockouts is insensitive to the
purine nucleotide, GDP, that very e¡ectively inhibits
UCP1 activity. Monemdjou et al. show that GDP
inhibits proton leak in mitochondria isolated from
control mice by approximately 50%; under the
same incubation conditions, GDP has no e¡ect on
leak in mitochondria from Ucp1 knockout mice. Be-
cause BAT expresses Ucp2, Ucp3, and Ucp5 [93], as
well as Ucp1, their results show that any proton leak
that is caused by any of these UCPs is insensitive to
GDP. It is also interesting to note that despite the
5-fold increase in level of message for Ucp2 (reported
by Enerba«ck et al., [14]), and no change in the levels
of mRNA for Ucp3 (Kozak, unpublished ¢ndings),
there is no di¡erence in the amount of proton leak
between knockouts and controls when mitochondria
are incubated in the presence of saturating concen-
trations of GDP. Thus the level of message for Ucp2
is incongruent with the level of its putative function,
proton leak as assessed under their experimental con-
ditions (see discussion below).
A provocative series of experiments on the fatty
acid induction of proton leak in BAT mitochondria
from Ucp1 knockout and control mice have recently
been conducted by Nedergaard and Cannon and col-
leagues [56]. The experiments were predicated upon
the widely accepted notion that fatty acids liberated
from noradrenergic stimulation of lipolysis were the
intracellular activators of uncoupling in brown adi-
pocytes [67,68]. This hypothesis was bolstered over
many years by the results of numerous types of stud-
ies, such as those showing that fatty acids and fatty
acyl CoA esters could relieve purine nucleotide inhi-
bition of uncoupling activity (e.g. [12,70,83,84]).
Moreover, experiments using mitochondria isolated
from yeast that were transfected with Ucp1 (wild
type or mutated Ucp1) have suggested that a cysteine
residue near the C-terminal of UCP1 plays an im-
portant role in fatty acid activation of uncoupling
[24]. Other reports describe distinct sites for fatty
acid activation and nucleotide binding sites in studies
on isolated and liposome-reconstituted UCP1 [43].
The conclusion of Matthias et al. [56] that UCP1 is
not directly involved in the uncoupling e¡ect of fatty
acids in brown fat mitochondria was thus surprising.
The authors investigated the fatty acid-induced
changes in mitochondrial membrane potential and
oxygen consumption in BAT mitochondria from
Ucp1 knockout and control mice. Short and long
chain fatty acids were shown to decrease mitochon-
drial membrane potential, and increase oxygen con-
sumption in mitochondria from both Ucp1 knockout
mice and from controls. The substrate provided to
the mitochondria in these studies was glycerol-3-
phosphate, and rotenone was used in the incubations
to inhibit the oxidation of any endogenous substrate
through complex 1. Thus it cannot be argued that
fatty acids were being used as substrates for mito-
chondrial oxidation. Because their ¢ndings show that
fatty acids uncouple oxidative phosphorylation in
Ucp1 knockout mitochondria just as well as they
do in wild type control mitochondria, their ¢ndings
thus support the conclusion that free fatty acids are
not the intracellular activator of UCP1. Their report
is indeed provoking further studies on this speci¢c
question, and on the identi¢cation of the true phys-
iological activators of other UCPs [60].
It must be noted that the initial studies by Mon-
emdjou et al. [59] on the kinetics of mitochondrial
proton leak were conducted on mitochondria that
were isolated and incubated in the presence of 0.5%
defatted bovine serum albumin (BSA). Given more
recent ¢ndings on the e¡ects of fatty acids and pu-
rine nucleotides, it is possible to re-examine these
¢ndings, and re£ect further on the results of Mat-
thias et al. [56]. Relevant are the recent results of
Jaburek and colleagues [41] who expressed UCP2
and UCP3 in Escherichia coli and reconstituted the
BBABIO 44997 19-2-01
M.-E. Harper, J. Himms-Hagen / Biochimica et Biophysica Acta 1504 (2001) 159^172164
proteins into liposomes. Based on the results of their
ion £ux studies they conclude that puri¢ed UCP2
and UCP3 behave identically to UCP1. All three
catalyze electrophoretic £ux of protons and alkylsul-
fonates. They also show that £ux induced by each of
the three UCPs has an obligatory requirement for
fatty acids, and that there are large di¡erences in
the Ki values for nucleotide inhibition of the UCPs.
While the Ki for GDP inhibition of UCP1 activity is
17 WM, that for UCP2 and UCP3 are approximately
1.2 mM and 1.0 mM, respectively. The possible im-
plications of these ¢ndings for the earlier results of
Monemdjou et al. [59] and Matthias et al. [56] are as
follows. An obligatory requirement for fatty acids
would explain the low rates of leak-dependent oxy-
gen consumption observed by Monemdjou et al. [59]
since their mitochondria were studied in the presence
of 0.5% defatted BSA. The fact that Monemdjou et
al. [59] used a GDP concentration of 1.0 mM would
mean that while UCP1 activity would be fully inhib-
ited, the activity of UCP2 and UCP3 might only be
partially inhibited. While nucleotides could be an in
vivo regulator of UCP1 activity, it is unlikely that
they regulate the activities of UCP2 and UCP3 given
the high concentrations needed to inhibit them.
Thus, UCP2 and UCP3 could be active under con-
ditions where there are relatively high concentrations
in vivo of ADP, such as near state 4 respiration,
when a cell has very little need for ATP. UCP1
would not be active under these conditions given
its lower Ki for purine nucleotides. In fact the phos-
phorylation ratio in BAT cells would seem to have
little bearing on the activity of UCP1; this is evident
in the £ux control coe⁄cients for proton leak be-
tween Ucp1 knockout and control mitochondria [59].
The results of Matthias et al. [56] are interpreted
as showing that the fatty acid activation of uncou-
pling in BAT mitochondria is the same in mitochon-
dria regardless of the presence or the absence of
Ucp1. However, once again it must be noted that it
is not simply the absolute presence versus the ab-
sence of Ucp1 that was studied. We know that the
genetic removal of Ucp1 induces an upregulated ex-
pression of UCP2 mRNA; it is likely that there are
changes in the expression level of a number of other
inner membrane proteins. It is also known that other
members of the mitochondrial carrier protein family,
such as the adenylate carrier, can also catalyze fatty
acid-induced uncoupling [77]. It thus seems that in
order to accept the idea that fatty acids do not di-
rectly activate UCP1 activity, further corroborative
results are needed.
2.1.3. The Ucp3 knockout mouse
Two groups have simultaneously reported on the
creation and metabolic characteristics of transgenic
mice lacking Ucp3. Based on the high homology of
Ucp3 with Ucp1, and on its high levels of expression
in skeletal muscle and BAT, and its ability to dimin-
ish mitochondrial protonmotive force, Ucp3 was hy-
pothesized to play an important role in energy bal-
ance and thermoregulation. The ¢nding that thyroid
hormones increase the expression of Ucp3 [22,49,50]
is consistent with this hypothesis. Inconsistent with
this concept is the observation that fasting results in
increased expression of Ucp3. However, this has
been described as indicating a possible role for
UCP3 in the metabolism of the fatty acids liberated
during fasting. Another putative bene¢cial role for
the recently discovered UCPs is the decreased pro-
duction of reactive oxygen species (ROS), as has
been described for UCP2 [61].
Lowell’s group produced knockouts by electropo-
rating the targeting vector into J1 embryonic stem
cells and the targeted clones were then injected into
C57BL6 embryos [90]. Reitman and colleagues used
a 129/SvC embryonic stem cell line and the chimeric
mice that were heterozygous for the targeted allele
were crossed to Swiss Black mice [23]. Both groups
report that Ucp3 knockout mice are quite healthy, at
least at the ages studied, and are not more predis-
posed to obesity than control mice. The most striking
¢ndings of Lowell’s group were that skeletal muscle
mitochondria lacking UCP3 are better coupled (im-
proved respiratory control ratio (RCR)), and pro-
duce a signi¢cantly higher amount of ROS than con-
trol mitochondria. Based on the hypothesized role
for UCP3 in the metabolism of the fatty acids, it
was expected that the mice might demonstrate ab-
normal oxidation of lipids as assessed by indirect
calorimetry, and perhaps by abnormal serum lipid
pro¢les. The former was not observed in any of the
mice under any condition (e.g. exercise, fasting, feed-
ing a high fat diet), and the latter was only observed
in older (18^24 weeks) mice when fed a high fat diet.
Their ¢ndings relating the absence of UCP3 in
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muscle to the production of ROS are particularly
interesting. Two independent methods were used to
assess the production of ROS: lucigenin-derived
chemiluminescence (to detect superoxide anion pro-
duction), and mitochondrial aconitase activity (to
assess in vivo ROS inhibition of this mitochondrial
enzyme). As ROS are thought to underlie aging pro-
cesses, it will be interesting to see if the UCP3 knock-
out mouse ages at an accelerated rate, and has a
diminished maximum life span (see [30,80]). Poten-
tially relevant are the ¢ndings of Harper and col-
leagues who have shown that mitochondrial proton
leak is increased in hepatocytes of old compared to
young mice [34]. There is also evidence that caloric
restriction lowers mitochondrial proton leak in skel-
etal muscle from old rats (Harper, unpublished ob-
servations), and it is well demonstrated that caloric
restriction minimizes damage from ROS, and extends
maximum life span [80].
In the simultaneous report, Reitman and col-
leagues [23] similarly describe mice whose phenotype
at the whole body level is una¡ected by the absence
of UCP3. An important ¢nding from this group was
that mitochondrial proton leak is greatly reduced in
muscle, minimally reduced in BAT, and not altered
in liver mitochondria. The ¢ndings suggest that
UCP3 accounts for the majority of leak in skeletal
muscle. The overall kinetics of muscle proton leak
reactions are described by protonmotive force values
that are signi¢cantly greater than those for control
mitochondria ^ consistent with the absence of a pro-
tein that uncouples oxidative phosphorylation. De-
spite the reductions in muscle mitochondrial proton
leak, no consistent phenotypic abnormalities at the
whole body level were observed. The knockout mice
were not obese and had normal serum insulin, trigly-
ceride, FFA and leptin levels. Circadian rhythms for
body temperature and motor activity were normal as
were body temperature responses to fasting, stress,
thyroid hormone, and cold exposure. Metabolic
rate and respiratory quotients as assessed by indirect
calorimetry were normal, and the responses in each
to fasting, thyroid hormone and to a L-3-adrenergic
agonist (CL 316,243) were normal; responses after
feeding a high fat diet were not assessed. Because
increases in basal metabolic rate in response to thy-
roid hormone treatment were the same in knockout
and control mice, their ¢ndings show that thyroid
thermogenesis does not require UCP3. Overall, while
the results show abnormal bioenergetic characteris-
tics in muscle mitochondria lacking UCP3, this does
not apparently have a signi¢cant e¡ect on metabolic
rate.
Thus both groups provide evidence supporting the
idea that mitochondrial proton leak, as it has been
traditionally de¢ned, is lower in skeletal muscle mi-
tochondria of Ucp3 knockout mice. This should not
however be interpreted as indicating that UCP3 is
thus a proton translocating protein. Even the mech-
anism of uncoupling for UCP1 is a matter of debate,
despite many years of study [19,44,47]. While it is
possible that UCP3 may use the same mechanism
for uncoupling as UCP1, it may cause electrophoret-
ic transport of other metabolites such as those re-
lated to fatty acid oxidation. The latter would be
consistent with the increased expression of UCP3
during fasting. Further studies utilizing skeletal
muscle mitochondria from these mice aim at eluci-
dating the transported moiety.
2.1.4. The Ucp1^Ucp3 double knockout mouse
To determine whether the phenotype of the Ucp1
knockout mouse would be made more severe by the
genetic removal of Ucp3, the double Ucp1^Ucp3
knockout mouse was bred [23]. As described above,
the Ucp1 knockout mouse has a reduced thermogen-
ic response to a L-3-adrenergic agonist, and is cold-
sensitive [14]. The double knockout mice however
did not have any further reduction in their response
to L-3-adrenergic stimulation, and were no more sen-
sitive to cold compared to the Ucp1 knockout. Thus
these results suggest that Ucp3 is not a modi¢er gene
of the Ucp1 knockout phenotype. It would be inter-
esting to see whether the tendency towards higher
circulating levels of fatty acids on older Ucp3 knock-
out mice fed a high fat diet is accentuated in the
Ucp1^Ucp3 double knockout mouse, given that fatty
acid oxidation to support UCP1 activity is normally
important, especially at colder environmental tem-
peratures.
2.1.5. The Ucp2 knockout mouse
Reports on production of Ucp2 knockout mice are
imminent from two laboratories. A discussion of the
phenotypes of these models awaits the o⁄cial publi-
cations.
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2.1.6. The adenine nucleotide translocator 1 (Ant1)
knockout mouse
To create a mouse model of tissue-speci¢c mito-
chondrial disease, Wallace and colleagues generated
mice that are de¢cient in Ant1 [25]. Mice normally
have two Ant genes, Ant1 which is expressed in skel-
etal muscle, heart, and brain, and Ant2 which is ex-
pressed in all tissues except skeletal muscle. Thus,
skeletal muscle of the Ant1 knockout mice is devoid
of any known adenine nucleotide transporters, while
brain and heart express the Ant2 isoform, and thus
are only partly de¢cient in transporter activity. Ant1
knockout mice exhibit severe exercise intolerance,
and the classical anatomical, histological, biochemi-
cal, metabolic and physiological features associated
with the development of myopathy and hypertrophic
cardiomyopathy. Biochemically, skeletal muscle mi-
tochondria of knockout mice have defective ADP-
stimulated (i.e. state 3) respiration (most substrates),
consistent with the absence of ADP/ATP transport.
State 4 rates were comparable between knockouts
and controls. As a result of the lower state 3 rates,
respiratory control ratios were 2^3-fold lower in
knockouts than in controls. There was also a marked
proliferation of mitochondria in skeletal muscle sug-
gesting a compensatory proliferation of mitochon-
dria.
Sequential studies revealed that mitochondria from
skeletal muscle, heart and brain of the Ant1 knock-
out mice produce dramatically higher amounts of the
ROS, hydrogen peroxide [15]. The increased ROS
elicits manganese superoxide dismutase activity in
muscle and heart. Glutathione peroxidase-1 activity
is moderately increased in both tissues. Mitochon-
drial rearrangements in mtDNA occurred in knock-
outs and were higher in heart than in skeletal muscle,
consistent with the lower degree of antioxidant de-
fenses in the heart. Whether or not there are any
changes in the levels of expression of other UCPs
is not as yet known.
2.2. Overexpression or ectopic expression of UCPs
2.2.1. The aP2-Ucp(1) mouse
Before the identi¢cation of UCP2 and the other
putative UCPs, Kozak and collaborators produced
the aP2-Ucp mouse to test the idea that UCP(1)
could provide defense against obesity if expressed
not only in BAT, but also in WAT [45]. To do this
they used the adipose-speci¢c promoter aP2 to direct
the expression of Ucp1. The presence of transgenic
UCP1 in BAT results in downregulation of the en-
dogenous gene so that BAT becomes relatively de¢-
cient in Ucp1 expression under the control of its own
promoter. The actual amount of UCP1 protein in
BAT is relatively normal. As hypothesized however,
the expression of the transgene in adipose tissues
results in reductions in total body weight and sub-
cutaneous fat stores in the genetically obese Avy
mouse. Further studies showed that diet-induced
obesity in C57BL6J mice was also mitigated by the
ectopic expression of Ucp1 in WAT [46]. In the lat-
ter, feed e⁄ciency (weight gain per unit of dietary
energy intake) was 50% of the e⁄ciency of non-
transgenic control mice. The expression of the trans-
gene was however not su⁄cient to allow a normal
thermogenic response to an acute dose of norepi-
nephrine, or in homozygotes, to cold, and the dose
of transgene was inversely correlated to the degree
of thermogenic response [81]. The authors attribute
the impaired heat production to the potentially
detrimental e¡ects of the early expression of Ucp1
during di¡erentiation (controlled by the aP2 pro-
moter in these transgenic mice); normally Ucp1 ex-
pression occurs later during di¡erentiation. These
¢ndings, in conjunction with the ¢ndings from
Ucp1-de¢cient mice (above), indicate that BAT be-
stows the unique function of adaptation to acute
cold. The high levels of Ucp1 expression in BAT,
plus the unique anatomical features of BAT (arte-
rio-venous anastamoses, high degree of sympathetic
innervation) make it an e⁄cient producer and ex-
porter of heat.
2.2.2. The human Ucp3 (hUcp3)-overexpressing
mouse
The question of the physiological e¡ects of the
increased expression of Ucp3 has very recently been
addressed by one group [10]. Clapham and col-
leagues generated a mouse line overexpressing
hUcp3 in muscle of C57BL6UCBA mice in which
transcription was driven from the mouse K-actin pro-
moter (in order to restrict gene expression to muscle).
By 8 weeks of age, transgenic males had signi¢cantly
lower body weights, despite increased food intake,
compared to wild type mice. Following the feeding
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of a palatable diet (condensed milk diet) the trans-
genics still displayed lower body weight despite in-
creased energy intakes. Mice overexpressing UCP3
were also more glucose-tolerant than wild type
mice. These results provide exciting evidence sup-
porting the idea that UCP3 can indeed a¡ect the
e⁄ciency of mitochondrial oxidative phosphoryla-
tion, and whole body energetics. Further detailed
analyses on skeletal muscle mitochondria will be of
signi¢cant interest.
3. Transgenic modi¢cation of extramitochondrial
factors a¡ecting the e⁄ciency of energy
transduction
3.1. Removal or reduction of the activators/factors
3.1.1. The protein kinase A (PKA)-RIIL knockout
mouse
Cyclic AMP (cAMP) is a well recognized intracel-
lular factor in the control of cellular energy metab-
olism. To study its signi¢cance, McKnight’s group in
1996 generated mice in which the PKA-RIIL subunit
of PKA was genetically disrupted [2,11]. Because the
e¡ects of cAMP are mediated through cAMP-depen-
dent PKA, and because the RIIL subunit of PKA is
abundant in BAT and WAT and the brain, it was
anticipated that the genetic removal of this key reg-
ulatory element would clarify the physiological func-
tions of PKA in energy metabolism. While their ¢nd-
ings con¢rm the importance of the regulatory
subunit, what is also very interesting is the compen-
satory switch to the use of the RIK isoform which
almost entirely replaces the lost RIIL isoform. As a
result the holoenzyme in transgenic adipose tissue
has a greater a⁄nity for cAMP and is constitutively
activated. The phenotypic outcome is decreased
adiposity despite normal food intake, and protection
against diet-induced obesity. Increased UCP1 expres-
sion and uncoupling activity are thus thought to ex-
plain at least partly the altered energy balance. How-
ever, Planas et al. [66] show that the lipolytic
response to isoproterenol and CL 316,243 is de¢-
cient, thus indicating that the compensatory switch
to the use of the RIK isoform is not fully compensa-
tory.
3.1.2. The hormone-sensitive lipase knockout mouse
Another intracellular mediator widely considered
as crucial for the activation of uncoupling in BAT
is hormone-sensitive lipase, as it hydrolyzes triacyl-
glycerol, releasing fatty acids which in turn have been
considered as activators of UCPs. Hormone-sensitive
lipase also is known to hydrolyze cholesterol esters in
tissues including the adrenals, ovaries, testes and
macrophages. It was anticipated that a hormone-sen-
sitive lipase knockout mouse would thus have defec-
tive cold-induced thermogenesis, and steroidogenesis.
Here, once again, is an example of ¢ndings that re-
fute widely accepted notions on the mechanisms ac-
tivating uncoupling. Notwithstanding the genetic in-
activation of hormone-sensitive lipase, mice are
neither obese nor cold-sensitive which must be inter-
preted as indicating alternate and as yet unknown
mechanisms that cause the liberation of fatty acids
to fuel BAT thermogenesis, and activate UCP1 ac-
tivity [64,92]. (However, see also the discussion above
on the results of Matthias et al. [56].) The only
phenotypic abnormality in knockouts was sterility
in males. Adipocytes in BAT and WAT were roughly
5-fold and 2-fold larger in knockouts compared with
controls, suggesting that hydrolysis of triacylglycerol
was to some extent a¡ected. However, knockout
mice retained approximately 40% of triacylglycerol
lipase activity relative to controls. Overall their re-
sults indicate that hormone-sensitive lipase cannot,
as earlier thought, be the sole lipolytic enzyme in
adipose tissues.
3.1.3. The L-3-adrenergic receptor knockout mouse
The activation of L-1-, L-2- or L-3-adrenergic re-
ceptors leads to increased adenylate cyclase activity
and cAMP levels. In adipose tissues, the latter acti-
vates PKA which then activates lipolysis in white
adipocytes, and uncoupling in brown adipocytes
[48]. The L-3-adrenergic receptor is expressed almost
exclusively in adipose tissues (brown and white), but
adipose tissues express all three types of receptors.
Because the L-3-adrenergic receptor is relatively re-
sistant to desensitization and downregulation [26], it
was hypothesized that it might maintain signaling
during periods of sustained sympathetic stimulation,
such as that in BAT during chronic exposure to cold,
or during diet-induced thermogenesis.
BBABIO 44997 19-2-01
M.-E. Harper, J. Himms-Hagen / Biochimica et Biophysica Acta 1504 (2001) 159^172168
To examine the physiology and pharmacology of
the L-3-adrenergic receptor, Lowell and collaborators
produced mice with targeted disruption of the L-3-
adrenergic receptor gene [85]. It was initially thought
that these mice might be obese, and perhaps have
defective thermoregulatory mechanisms. However,
the mice were found to have only a modest increase
in body fat. As observed in other gene knockout
mice, here again there was increased expression of
a related gene. L-1-Adrenergic receptor, but not L-
2-adrenergic receptor mRNA levels were upregu-
lated. However, their results show that the e¡ects
of the L-3 selective agonist, CL 316,243, such as adi-
pocyte triacylglycerol lipolysis, whole body energy
expenditure, and reduced food intake, are mediated
exclusively by L-3-adrenergic receptors.
Later studies by this same group showed interest-
ingly that a full thermogenic response to L-3-adren-
ergic receptor stimulation requires that receptors are
present in both brown and white adipocytes. It
seems, in other words, that both the ‘furnace’
(BAT thermogenesis) and the ‘fuel tanks’ (WAT tri-
acylglycerol stores) must be activated [27]. For these
studies, tissue-speci¢c L-3-adrenergic receptor trans-
genic constructs were injected into mouse zygotes
homozygous for the L-3-adrenergic receptor knock-
out allele.
It is interesting to note that L-3-adrenergic recep-
tor knockout mice having a di¡erent genetic back-
ground from those used by Lowell’s group (i.e. FVB/
N, FVB/NU129/SvJ, and 129/SvJ) are predisposed
to obesity. In mice having a 129/SvUC57BL6J back-
ground, Revelli et al. [69] report a 41% increase in
body fat content in knockouts compared to wild type
controls despite slight (non-signi¢cant) increases in
food intake. In contrast to the results of Susulic et
al. [85], who report a compensatory increase in
mRNA levels for the L-1-adrenergic receptors in
BAT and WAT of knockout mice, Revelli et al.
[69] observe a decrease in mRNA for the L-1-adren-
ergic receptor in BAT, and no change in levels in
WAT.
Ito et al. [40] produced a transgenic mouse that
expresses the human form of the L-3-adrenergic re-
ceptor rather than the murine form. This humanized
mouse should be useful in the development of drugs
that are e¡ective in treating human obesity given the
well known di¡erences in the a⁄nities of agonists
between rodent and human forms of the receptor
[4,13].
3.1.4. The dopamine L hydroxylase knockout mouse
Another mouse that was produced in order to
study mechanisms of thermogenesis and energy bal-
ance is the dopamine L hydroxylase knockout mouse
[87]. Dopamine L hydroxylase is the enzyme respon-
sible for the synthesis of noradrenaline and adrena-
line, the main e¡ectors of the adrenal medulla, and
the sympathetic nervous system, respectively. Be-
cause these e¡ectors promote the catabolism of tri-
glycerides and glycogen, activate thermogenesis in
BAT, and alter heat loss by modulating peripheral
vasoconstriction and piloerection, it was anticipated
that this knockout mouse would be cold-sensitive
and obese. As expected, the mice were cold-intoler-
ant due to defective BAT thermogenesis, and periph-
eral vasoconstriction. However, they were not obese,
in fact body weights were slightly lower in knockouts
than in controls. Moreover, the knockouts con-
sumed signi¢cantly greater amounts of dietary en-
ergy. Increased basal metabolic rate is reported.
However, oxygen consumption data were divided
through by the body weights of the animals (weights
of the knockouts are approximately 20% lower
than the controls) ; without knowing the percentage
of lean body mass of the mice, it is di⁄cult to ap-
preciate the signi¢cance of this ¢nding. (See also
[36].) If knockouts are treated with injections of
the synthetic amino acid precursor of norepineph-
rine, L-threo-3,4-dihydroxyphenylserine, levels of nor-
epinephrine are restored in many tissues, and
many phenotypic characteristics are restored (e.g.
UCP expression, male fertility, hind-limb extension)
[86].
3.2. Overexpression
3.2.1. The Glut4-overexpressing mouse
A recent report describes altered levels of expres-
sion of UCPs in transgenic mice in which the insulin
responsive glucose transporter, Glut4, is overex-
pressed [89]. Tsuboyama-Kasaoka and colleagues
created transgenic mice harboring Glut4 minigenes
with di¡ering lengths of the 5P-£anking sequence.
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The expression of the Glut4 transgenes was found to
alter not only the level of expression of Glut4, but
also the level of Ucp3. In skeletal muscle, BAT, and
WAT, the level of Glut4 expression was increased by
1.4^4.0-fold compared to control littermates. The
level of Ucp3 expression was increased by 4.0- and
1.8-fold in muscle and WAT, respectively. However,
the level of Ucp1 expression was decreased in BAT
by approximately 38%. Glut4-overexpressing mice
displayed a 16% increase in whole body oxygen con-
sumption (ml/min), a 14% decrease in blood glucose
concentration and a 68% increase in blood lactate
concentration. There were no changes in the levels
of circulating free fatty acids. Their results suggest
that, in addition to increased fatty acids, increased
glucose uptake by cells may result in increased ex-
pression of Ucp3 mRNA.
4. Summary and conclusion
While it may have been anticipated that the appli-
cation of transgenics to the area of mitochondrial
energetics would solve, or at least clarify, a number
of controversies, there have been as many questions
raised as there have been answers gained. The inter-
pretation of results from studies of transgenic mice is
often complicated by compensatory processes within
and beyond gene families of the gene being modi¢ed.
Given that mitochondria provide cellular energy con-
version pathways that underpin both cell life and
death, the presence of ‘back-up mechanisms’ is not
surprising. Increasingly noted are the signi¢cant ef-
fects that genetic background has on the phenotypes
of transgenic mice. The complex interactions between
genes, genetic background, and the environment will
likely prove to be important. Overall, the ¢ndings
from transgenic approaches to the study of mito-
chondrial e⁄ciency are best considered as valuable
additional tools in metabolic research.
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